TransQST

Translational quantitative systems toxicology to improve the understanding of the safety of medicines
TransQST logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 6
Grant agreement number
116030

Contributions
IMI Funding
8 000 000
EFPIA in kind
7 802 874
Other
0
Total Cost15 802 874

Summary

When developing a new medicine, determining whether or not it will be safe for patients to take remains a challenge, and adverse drug reactions (ADRs) remain a major issue for clinicians. Of particular concern is damage to vital organs such as the liver, kidney, cardiovascular and gastrointestinal systems. The TransQST project will gather together data (both new and existing) and develop tools that will make it easier to assess the safety profile of potential medicines. They will also work to add to our understanding of when results in animal tests can be reliably extrapolated to humans, and develop models to predict concentrations of medicines in tissues, an important element of safety assessments. Another project output will be improved methods to visualise and analyse complex datasets during decision making on drug safety.

Participants Show participants on map

EFPIA companies
  • AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany
  • AstraZeneca AB, Södertälje, Sweden
  • Eli Lilly and Company Ltd, Basingstoke, United Kingdom
  • Glaxosmithkline Research And Development LTD, Brentford, Middlesex, United Kingdom
  • Institut De Recherches Internationales Servier, Suresnes, France
  • Janssen Pharmaceutica NV, Beerse, Belgium
  • Orion Corporation, Espoo, Finland
  • Sanofi-Aventis Research and Development, Chilly Mazarin, France
Universities, research organisations, public bodies, non-profit groups
  • Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands
  • European Molecular Biology Laboratory, Heidelberg, Germany
  • Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V., Dortmund, Germany
  • Fundació Institut Mar d’investigacions Mèdiques (IMIM), Barcelona, Spain
  • Simcyp Limited, London, United Kingdom
  • UNIVERSITAETSKLINIKUM Aachen, Aachen, Germany
  • Universiteit Leiden, Leiden, Netherlands
  • Universiteit Maastricht, Maastricht, Netherlands
  • University of Liverpool, Liverpool, United Kingdom
  • University of Oxford, Oxford, United Kingdom
  • Universität Wien, Vienna, Austria
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • OcellO B.V., Leiden, Netherlands
  • Synapse Research Management Partners S.L, Barcelona, Spain

CONTACT

Project coordinator
Kevin Park
University of Liverpool
b.k.park[at]liverpool.ac.uk
Project contact
info[at]transqst.org